Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ASCO guidance recommends Iressa

Executive Summary

American Society of Clinical Oncology recommends use of AstraZeneca's Iressa for treatment of non-small cell lung cancer in updated guidance published in 1Journal of Clinical Oncology. FDA approved Iressa (gefinitib) May 5 (2"The Pink Sheet" May 12, 2003, p. 7)...

You may also be interested in...

Iressa Use Should Not Be Limited By EGFR Mutation Testing, Researchers Say

Data suggesting that the efficacy of Iressa is associated with an EGFR gene mutation should not stem use of anti-EGFR agents in mutation-negative patients, researchers said

Iressa Approval Upholds Standard For Oncology Subpart H Approvals – FDA

The Iressa approval upholds the current standard of approval for oncology drugs under the Subpart H accelerated approval regulations, FDA maintains

Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back

A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts